Business · 30/06/2021Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for AXONICS Sacral Neuromodulation System Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of AXONICS' Sacral Neuromodulation System, as required by law, following a submission to the US Patent and Trademark Office (USPTO)
Original source language: Federal Register — Food and Drug AdministrationOpen original release →